跳至主要内容
临床试验/NCT00621855
NCT00621855已完成2 期

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

Boehringer Ingelheim167 个研究点 分布在 8 个国家目标入组 1,878 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
1,878
试验地点
167
主要终点
Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time

研究概览

简要总结

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Dabigatran etexilate 50mg

Experimental

twice daily dosing,

干预措施: dabigatran etexilate (Drug)

Dabigatran etexilate 75mg

Experimental

twice daily dosing, patients with moderate renal impairment allocated 50mg bid

干预措施: dabigatran etexilate (Drug)

Dabigatran etexilate 110mg

Experimental

twice daily dosing, patients with moderate renal impairment allocated 75mg bid

干预措施: dabigatran etexilate (Drug)

dabigatran etexilate 150mg

Experimental

twice daily dosing, patients with moderate renal impairment allocated 110mg bid

干预措施: dabigatran etexilate (Drug)

placebo

Placebo Comparator

matched placebo

干预措施: placebo (Drug)

结局指标

主要结局

Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time

时间窗: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed. A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells. All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

次要结局

  • Number of Participants With Any Reduction of D-dimer Concentration(at 1 week and 4 weeks)
  • Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment(6 month treatment period + 2 week post treatment follow up)
  • Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment(6 month treatment period + 2 week post treatment follow up)
  • Change From Baseline in log10 D-dimer After 1 and 4 Weeks(Baseline and at 1 week and 4 weeks)
  • Number of Participants With Bleeding Events During Total Observation Time(6 month treatment period + 2 week post treatment follow up)
  • Laboratory Analyses(6 month treatment period + 2 week post treatment follow up)

研究者

申办方类型
Industry

研究点 (167)

Loading locations...

相似试验